Pharmaceutical companies by P/S ratio
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Roivant Sciences leads the 50 pharmaceutical companies ranked by P/S ratio, at 3387, ahead of Dianthus Therapeutics (2352) and Protagonist Therapeutics (180). Figures as of 18 Nov 2026, 20:24 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 50
- First
- Roivant Sciences3387
- Median
- 6.9
- Combined market value
- ZAR 87.71T
- Countries
- 10
- Not ranked
- 11no P/S ratio on file
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | P/S ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | Roivant SciencesROIV · Health Care | 3387 | ZAR 483.7B | ZAR 667.51 | 0.25% down | 90% up | ||
| 2 | Dianthus TherapeuticsDNTH · Health Care | 2352 | ZAR 82.8B | ZAR 1,469.68 | 2.25% down | 113% up | ||
| 3 | Protagonist TherapeuticsPTGX · Health Care | 180 | ZAR 142.8B | ZAR 2,188.45 | 1.55% up | 46% up | ||
| 4 | CytokineticsCYTK · Health Care | 81.7 | ZAR 124.3B | ZAR 892.15 | 0.08% down | 20% down | ||
| 5 | Rhythm PharmaceuticalsRYTM · Health Care | 43.4 | ZAR 142.5B | ZAR 2,054.65 | 1.93% up | 13% up | ||
| 6 | InsmedINSM · Health Care | 43.3 | ZAR 454.4B | ZAR 2,071.33 | 1.67% down | 40% down | ||
| 7 | BridgeBio PharmaBBIO · Health Care | 30.2 | ZAR 262.3B | ZAR 1,346.60 | 1.43% up | 17% up | ||
| 8 | Ligand PharmaceuticalsLGND · Health Care | 22.3 | ZAR 103.2B | ZAR 5,159.27 | 1.58% up | 43% up | ||
| 9 | Ascendis PharmaASND · Health Care | 22.2 | ZAR 307.3B | ZAR 4,684.67 | 0.07% down | 28% up | ||
| 10 | Eli LillyLLY · Health Care | 19.0 | ZAR 21.37T | ZAR 23,991.14 | 1.96% down | 35% up | ||
| 11 | Royalty PharmaRPRX · Health Care | 16.7 | ZAR 686.9B | ZAR 1,194.57 | 0.62% up | 78% up | ||
| 12 | TG TherapeuticsTGTX · Health Care | 16.2 | ZAR 172.4B | ZAR 1,140.90 | 5.25% up | 107% up | ||
| 13 | Mirum PharmaceuticalsMIRM · Health Care | 11.6 | ZAR 104.3B | ZAR 1,597.43 | 0.50% up | 31% up | ||
| 14 | Vertex PharmaceuticalsVRTX · Health Care | 11.4 | ZAR 2.36T | ZAR 9,302.54 | 0.74% up | 27% up | ||
| 15 | Axsome TherapeuticsAXSM · Health Care | 11.1 | ZAR 122B | ZAR 2,319.04 | 1.32% down | 7% down | ||
| 16 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | 11.0 | ZAR 129B | ZAR 1,642.20 | 0.12% down | 126% up | ||
| 17 | Travere TherapeuticsTVTX · Health Care | 9.9 | ZAR 83.8B | ZAR 873.13 | 1.15% down | 44% up | ||
| 18 | Corcept TherapeuticsCORT · Health Care | 9.8 | ZAR 128.7B | ZAR 1,175.99 | 2.91% down | 8% down | ||
| 19 | Madrigal PharmaceuticalsMDGL · Health Care | 9.7 | ZAR 160B | ZAR 6,889.80 | 5.55% down | 24% down | ||
| 20 | BeOne MedicinesONC · Health Care | 8.6 | ZAR 797.1B | ZAR 6,977.96 | 2.32% down | 17% up | ||
| 21 | GenmabGMAB · Health Care | 8.5 | ZAR 545.2B | ZAR 884.19 | 1.56% down | 70% up | ||
| 22 | AbbVieABBV · Health Care | 8.3 | ZAR 8.76T | ZAR 4,954.43 | 2.12% down | 26% up | ||
| 23 | United TherapeuticsUTHR · Health Care | 7.8 | ZAR 426.9B | ZAR 10,023.29 | 0.73% down | 23% up | ||
| 24 | Arrowhead PharmaceuticalsARWR · Health Care | 7.4 | ZAR 106B | ZAR 749.53 | 0.86% up | 10% up | ||
| 25 | Johnson & JohnsonJNJ · Health Care | 7.0 | ZAR 11.39T | ZAR 4,733.33 | 1.75% down | 38% up | ||
| 26 | Regeneron PharmaceuticalsREGN · Health Care | 6.8 | ZAR 1.69T | ZAR 16,364.42 | 1.16% down | 36% up | ||
| 27 | Alnylam PharmaceuticalsALNY · Health Care | 5.4 | ZAR 346.1B | ZAR 2,584.04 | 4.48% down | 66% down | ||
| 28 | NovartisNVS · Health Care | 5.4 | ZAR 5.07T | ZAR 2,683.18 | 2.46% down | 25% up | ||
| 29 | AlkermesALKS · Health Care | 5.3 | ZAR 135.2B | ZAR 804.68 | 2.42% up | 58% up | ||
| 30 | Merck & CoMRK · Health Care | 5.3 | ZAR 5.9T | ZAR 2,394.84 | 3.37% down | 51% up | ||
| 31 | Ionis PharmaceuticalsIONS · Health Care | 4.9 | ZAR 79.8B | ZAR 479.26 | 2.84% up | 64% down | ||
| 32 | AstraZenecaAZN · Health Care | 4.7 | ZAR 4.8T | ZAR 3,096.24 | 1.73% down | 2% up | ||
| 33 | Abbott LaboratoriesABT · Health Care | 4.1 | ZAR 3.14T | ZAR 1,814.89 | 0.27% up | 17% down | ||
| 34 | Novo NordiskNVO · Health Care | 3.8 | ZAR 3.01T | ZAR 681.94 | 3.07% down | 17% down | ||
| 35 | Jazz PharmaceuticalsJAZZ · Health Care | 3.7 | ZAR 273.6B | ZAR 4,262.54 | 2.44% up | 37% up | ||
| 36 | ZoetisZTS · Health Care | 3.7 | ZAR 606.9B | ZAR 1,493.71 | 3.51% up | 29% down | ||
| 37 | BioMarin PharmaceuticalBMRN · Health Care | 3.7 | ZAR 205.4B | ZAR 1,060.51 | 4.85% up | 11% up | ||
| 38 | Dr. Reddy's LaboratoriesRDY · Health Care | 3.5 | ZAR 216.3B | ZAR 259.47 | 1.49% up | 5% up | ||
| 39 | Legend BiotechLEGN · Health Care | 3.1 | ZAR 54.4B | ZAR 280.56 | 0.74% up | 42% down | ||
| 40 | PTC TherapeuticsPTCT · Health Care | 2.9 | ZAR 86.8B | ZAR 1,038.82 | 0.44% down | 20% down | ||
| 41 | Elanco Animal HealthELAN · Health Care | 2.9 | ZAR 232.4B | ZAR 464.92 | 4.04% up | 20% up | ||
| 42 | Teva Pharmaceutical IndustriesTEVA · Health Care | 2.9 | ZAR 850.5B | ZAR 728.88 | 1.07% down | 74% up | ||
| 43 | PfizerPFE · Health Care | 2.6 | ZAR 2.77T | ZAR 486.18 | 1.21% down | 14% up | ||
| 44 | Bristol-Myers SquibbBMY · Health Care | 2.5 | ZAR 2.12T | ZAR 1,036.49 | 2.27% down | 34% up | ||
| 45 | Amneal PharmaceuticalsAMRX · Health Care | 2.5 | ZAR 131.3B | ZAR 376.75 | 3.20% up | 83% up | ||
| 46 | Takeda PharmaceuticalTAK · Health Care | 2.4 | ZAR 1.18T | ZAR 368.11 | 1.59% down | 54% up | ||
| 47 | SanofiSNY · Health Care | 2.3 | ZAR 1.96T | ZAR 815.65 | 0.73% down | 4% down | ||
| 48 | GSKGSK · Health Care | 2.3 | ZAR 1.69T | ZAR 842.36 | 1.04% down | 6% up | ||
| 49 | ViatrisVTRS · Health Care | 1.6 | ZAR 405.4B | ZAR 353.59 | 0.02% up | 96% up | ||
| 50 | GrifolsGRFS · Health Care | 0.7 | ZAR 99.4B | ZAR 146.07 | 2.09% down | 1% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. P/S divides today's market value by the latest fiscal year's revenue from the annual report. Sums are converted from US dollars at today's exchange rate (1 USD = 17.2863 ZAR). 11 companies have no P/S ratio on file and are not ranked here.
Questions and answers
Which pharmaceutical companies rank first by P/S ratio?
Roivant Sciences (3387), Dianthus Therapeutics (2352) and Protagonist Therapeutics (180) are the top three of the 50 pharmaceutical companies ranked by P/S ratio as of 18 Nov 2026, 20:24 UTC.
How many pharmaceutical companies are in this ranking?
50 are ranked by P/S ratio. 11 more have no P/S ratio on file and are left out rather than ranked at zero.
What are these pharmaceutical companies worth together?
The 50 pharmaceutical companies ranked by P/S ratio have a combined market value of ZAR 87.71T as of 18 Nov 2026, 20:24 UTC.
What does ranking by P/S ratio measure?
Market value divided by the latest fiscal year's revenue: what the market pays for each dollar of sales.
Learn how this ranking works
All markets guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Pharmaceutical companies by P/S ratio”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=ps-ratio
Underlying data: Yahoo Finance; SEC EDGAR.